BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1860682)

  • 1. Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure.
    Langley PG; Keays R; Hughes RD; Forbes A; Delvos U; Williams R
    Hepatology; 1991 Aug; 14(2):251-6. PubMed ID: 1860682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan.
    Suzuki T; Ota K; Naganuma S; Koshikawa S; Hirasawa Y; Nakagawa S; Otsubo O; Akizawa T
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():46-54. PubMed ID: 1962904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing regular hemodialysis.
    Toulon P; Jacquot C; Capron L; Frydman MO; Vignon D; Aiach M
    Thromb Haemost; 1987 Jun; 57(3):263-8. PubMed ID: 3660328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of continuous low-dose intravenous heparin administered during operation on postoperative measurements of antithrombin III and antifactor Xa.
    Jennings SA; Heather BP; Greenhalgh RM
    Surgery; 1984 Sep; 96(3):550-5. PubMed ID: 6474360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
    Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D
    Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin.
    Hoffmann JN; Wiedermann CJ; Juers M; Ostermann H; Kienast J; Briegel J; Strauss R; Warren BL; Opal SM;
    Thromb Haemost; 2006 May; 95(5):850-6. PubMed ID: 16676077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin response and clearance in acute and chronic liver disease.
    Sette H; Hughes RD; Langley PG; Gimson AE; Williams R
    Thromb Haemost; 1985 Oct; 54(3):591-4. PubMed ID: 4089794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antithrombin III substitution for optimization of the heparin effect during extracorporeal circulation in heart surgery].
    Dietrich W; Schroll A; Göb E; Barankay A; Richter JA
    Anaesthesist; 1984 Sep; 33(9):422-7. PubMed ID: 6496919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of antithrombin iii concentrations during cardiopulmonary surgery].
    Sonzogni V; Bellavita P; Carrara B; Cossolini M; Ferri F; Fabretti F; Mamprin F; Pelliccioli I
    Minerva Anestesiol; 2000; 66(1-2):17-23. PubMed ID: 10736978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anticoagulation in hemodialysis sessions with a low molecular weight heparin (CY 222, Choay). Dosage studies in chronic hemodialysis. Its use in patients at high risk of hemorrhage].
    Dieval J; Morinière P; Roussel B; Bayrou B; Fournier A; Delobel J
    J Mal Vasc; 1987; 12 Suppl B():114-8. PubMed ID: 2834482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of serum level of antithrombin-III antigen, antithrombin activity, and its ratio of AT-III-heparin complex formation in maintenance hemodialysis patients].
    Yoshida K; Saka M; Kaneko Y; Kubota K; Hirao Y; Okajima E; Ishida M; Kihouin K; Motomiya Y
    Nihon Jinzo Gakkai Shi; 1989 Nov; 31(11):1171-7. PubMed ID: 2625740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antithrombin III substitution in dialysis-dependent renal insufficiency].
    Schrader J; Köstering H; Kramer P; Scheler F
    Dtsch Med Wochenschr; 1982 Dec; 107(48):1847-50. PubMed ID: 7140568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet factor 4 release induced by intravenous administration of heparin.
    Cella G; Scattolo N; Cappellato MG; Girolami A; Strauss WE; Sasahara AA
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(1):165-74. PubMed ID: 2581862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of heparin in uremic patients during hemodialysis].
    Cullmann W; Glöckner WM; Müller N
    Fortschr Med; 1981 Mar; 99(12):410-2. PubMed ID: 7227936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodialysis without anticoagulants: efficiency and hemostatic aspects.
    Casati S; Moia M; Graziani G; Cantaluppi A; Citterio A; Mannucci PM; Ponticelli C
    Clin Nephrol; 1984 Feb; 21(2):102-5. PubMed ID: 6723110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin and prostacyclin.
    Camici M; Evangelisti L
    Angiology; 1989 Apr; 40(4 Pt 1):294-9. PubMed ID: 2650580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Alteration in coagulation and fibrinolysis after burn injury and significance of anticoagulation therapy using heparin and antithrombin III concentrate].
    Ono I
    Hokkaido Igaku Zasshi; 1987 Jan; 62(1):108-21. PubMed ID: 3817736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevention of thromboembolism during pregnancy in 3 sisters with congenital antithrombin III deficiency and decreased inducible fibrinolysis].
    Schoch U; Zanetti E; von Felten A
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1807-10. PubMed ID: 2962279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of erythropoietin treatment on the coagulation system during standardized hemodialysis.
    Clyne N; Lins LE; Egberg N
    Clin Nephrol; 1995 Apr; 43(4):260-7. PubMed ID: 7606881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.